Given the data obtained from our work, further studies involving a larger and multicentric cohort of patients would be necessary to validate the role of anti-β2-GPI/PF4 antibodies in diagnosing patients with APS, clinical associations, and risk stratification. Here, PF4 is linked to autoimmune polyendocrinopathy.